消化内镜镇静相关急性并发症(ProSed 2研究):镇静相关并发症前瞻性多中心电子登记研究结果
在39个研究中心的电子内镜记录中前瞻性登记2011年12月至2014年8月的镇静相关急性并发症,共记录368206例内镜检查,11%未镇静,丙泊酚为最主要药物。镇静患者中38例(0.01%)发生重大并发症,总死亡率为0.005%(n=15),轻微并发症发生率为0.3%。多因素分析显示美国麻醉医师协会分级>2级(OR 2.29)及内镜类型和持续时间是所有并发症的独立危险因素。
要点
- 严重急性镇静相关并发症罕见,总死亡率为0.005%(n=15)。
- 丙泊酚单药镇静并发症发生率最低(OR 0.75,以咪达唑仑为参照)。
- 美国麻醉医师协会分级>2级(OR 2.29)为所有并发症的独立危险因素。
核心结论
- 这项大型多中心登记研究证实,消化内镜中严重急性镇静相关并发症罕见,死亡率极低。
- 数据有助于制定适应风险因素的镇静管理方案,以进一步预防特定患者的镇静相关并发症。
研究设计与样本
- 前瞻性多中心电子登记研究,于2011年12月至2014年8月在39个研究中心记录镇静相关急性并发症,中位纳入期为24个月。
- 共记录368206例内镜检查,其中11%未镇静;镇静方案由各研究中心决定。
主要发现
- 丙泊酚为最主要药物(62%单用,22.5%与咪达唑仑联用)。
- 镇静患者中38例(0.01%)发生重大并发症,总死亡率为0.005%(n=15),轻微并发症发生率为0.3%。
- 多因素分析显示所有并发症的独立危险因素包括美国麻醉医师协会分级>2级(OR 2.29)及内镜类型和持续时间。
- 与咪达唑仑(参照)相比,丙泊酚单药镇静并发症发生率最低(OR 0.75),联合方案OR为1.0-1.5。
- 与初级保健医院相比,三级转诊中心并发症发生率更高(OR 1.61);与两人内镜团队(内镜医师/助手,占所有操作的53.5%)相比,增加另一人负责镇静与更高的并发症发生率相关(OR 1.40-4.46),可能由于多因素分析中未显现的操作复杂性更高。
临床怎么用
- 作者认为数据有助于制定适应风险因素的镇静管理方案,以进一步预防特定患者的镇静相关并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sedation has been established for GI endoscopic procedures in most countries, but it is also associated with an added risk of complications. Reported complication rates are variable due to different study methodologies and often limited sample size. DESIGNS: Acute sedation-associated complications were prospectively recorded in an electronic endoscopy documentation in 39 study centres between December 2011 and August 2014 (median inclusion period 24 months). The sedation regimen was decided by each study centre. RESULTS: A total of 368 206 endoscopies was recorded; 11% without sedation. Propofol was the dominant drug used (62% only, 22.5% in combination with midazolam). Of the sedated patients, 38 (0.01%) suffered a major complication, and overall mortality was 0.005% (n=15); minor complications occurred in 0.3%. Multivariate analysis showed the following independent risk factors for all complications: American Society of Anesthesiologists class >2 (OR 2.29) and type and duration of endoscopy. Of the sedation regimens, propofol monosedation had the lowest rate (OR 0.75) compared with midazolam (reference) and combinations (OR 1.0-1.5). Compared with primary care hospitals, tertiary referral centres had higher complication rates (OR 1.61). Notably, compared with sedation by a two-person endoscopy team (endoscopist/assistant; 53.5% of all procedures), adding another person for sedation (nurse, physician) was associated with higher complication rates (ORs 1.40-4.46), probably due to higher complexity of procedures not evident in the multivariate analysis. CONCLUSIONS: This large multicentre registry study confirmed that severe acute sedation-related complications are rare during GI endoscopy with a very low mortality. The data are useful for planning risk factor-adapted sedation management to further prevent sedation-associated complications in selected patients. TRIAL REGISTRATION NUMBER: DRKS00007768; Pre-results.
引用
- Behrens A, Kreuzmayr A, Manner H, et al. Acute sedation-associated complications in GI endoscopy (ProSed 2 Study): results from the prospective multicentre electronic registry of sedation-associated complications. Gut. 2018. PMID: 29298872. doi:10.1136/gutjnl-2015-311037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。